Current and historical daily PE Ratio for Prescient Therapeutics Ltd (
ASX:PTX
) from 1990 to May 11 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Prescient Therapeutics stock (ASX:PTX) PE ratio as of May 11 2024 is 0.
More Details
Prescient Therapeutics Ltd (ASX:PTX) PE Ratio (TTM) Chart
Prescient Therapeutics Ltd (ASX:PTX) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1263
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Prescient Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-11 | At Loss | 2024-03-11 | At Loss |
| 2024-05-10 | At Loss | 2024-03-08 | At Loss |
| 2024-05-09 | At Loss | 2024-03-07 | At Loss |
| 2024-05-08 | At Loss | 2024-03-06 | At Loss |
| 2024-05-07 | At Loss | 2024-03-05 | At Loss |
| 2024-05-06 | At Loss | 2024-03-04 | At Loss |
| 2024-05-03 | At Loss | 2024-03-01 | At Loss |
| 2024-05-02 | At Loss | 2024-02-29 | At Loss |
| 2024-05-01 | At Loss | 2024-02-28 | At Loss |
| 2024-04-30 | At Loss | 2024-02-27 | At Loss |
| 2024-04-29 | At Loss | 2024-02-26 | At Loss |
| 2024-04-26 | At Loss | 2024-02-23 | At Loss |
| 2024-04-25 | At Loss | 2024-02-22 | At Loss |
| 2024-04-24 | At Loss | 2024-02-21 | At Loss |
| 2024-04-23 | At Loss | 2024-02-20 | At Loss |
| 2024-04-22 | At Loss | 2024-02-19 | At Loss |
| 2024-04-19 | At Loss | 2024-02-16 | At Loss |
| 2024-04-18 | At Loss | 2024-02-15 | At Loss |
| 2024-04-17 | At Loss | 2024-02-14 | At Loss |
| 2024-04-16 | At Loss | 2024-02-13 | At Loss |
| 2024-04-15 | At Loss | 2024-02-12 | At Loss |
| 2024-04-12 | At Loss | 2024-02-09 | At Loss |
| 2024-04-11 | At Loss | 2024-02-08 | At Loss |
| 2024-04-10 | At Loss | 2024-02-07 | At Loss |
| 2024-04-09 | At Loss | 2024-02-06 | At Loss |
| 2024-04-08 | At Loss | 2024-02-05 | At Loss |
| 2024-04-05 | At Loss | 2024-02-02 | At Loss |
| 2024-04-04 | At Loss | 2024-02-01 | At Loss |
| 2024-04-03 | At Loss | 2024-01-31 | At Loss |
| 2024-04-02 | At Loss | 2024-01-30 | At Loss |
| 2024-04-01 | At Loss | 2024-01-29 | At Loss |
| 2024-03-29 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
Prescient Therapeutics Ltd (ASX:PTX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Prescient Therapeutics Ltd
NAICS : 325412
ISIN : AU000000PTX3
Compare
Compare
Traded in other countries / regions
PTX.AustraliaUDD.GermanyPSTTF.USA IPO Date
1986-12-19Description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers